Making us sweatAll the scientific data has looked very good to me. Not sure why Boston group or other investors would be making us sweat here, maybe just wanting to negotiate a better price. They have considerable leverage if they are the only investor PMN is courting. Perhaps PMN is looking at other offers or exploring licensing or JVs or other mechanisms.
I just look at the science, the IP, and the market opportunity. At some point, I just have trust that management is working in the best interest of the shareholders, especially given this is a Nasdaq-listed company now. However, I've had several penny stocks w/ great tech go belly up in the past, and their technology magically ends up in the hands of another company with no recourse for shareholders other than court. I don't get the sense that this is the case here, but it would be great to get some updates.
This issue is one of the primary reasons I moved half my investment over to ABOS, since they are already funded through Phase 2. I still think PMN has a better product and have been adding to my PMN position during these dips since then.